Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SPC 100270

Known as: SPC-100270 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

safingol
sphinganine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1998
Highly Cited
1998
Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of…
The stress-activated protein kinase (SAPK) and mitogen-activated protein kinase (MAPK) cascades mediate cytotoxic and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
1996
Review
1996
Pre-clamp cardioprotection by protein kinase C (PKC) inhibitor improves left ventricular function following canine normothermic arrest.
Since protein kinase C (PKC) has been proven to be a mediator of neutrophil activation and of intracellular calcium homeostasis… Expand
1995
1995
Stereo-specific analysis of a novel protein kinase C inhibitor.
SPC-100270 drug substance ((2S,3S)-2-aminooctadecane-1,3-diol) is a synthetic sphingosine analogue possessing limited ultraviolet… Expand
1994
1994
SPC‐100270, a protein kinase C inhibitor, reduced hypoxic injury due to reperfusion following orthotopic liver transplantation in the rat
Abstract Recently, we reported that SPC‐100270, a sphingosine derivative and inhibitor of protein kinase C (50–90 μM) in mixed… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE